Physician profile
Ryan T Sankovic
NPI 1790270916
$11,251.10
in general payments reported to CMS, 2019-2025
29 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 75% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $161 · 2021: $45.40 · 2022: $1,276 · 2023: $1,983 · 2024: $6,366 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,804 · Travel and Lodging: $1,833 · Consulting Fee: $825 · Education: $51.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,803.64 |
| Travel and Lodging | $1,832.57 |
| Consulting Fee | $825.00 |
| Education | $51.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,387.15 | 2019-2025 | Wavewriter Alpha Prime 16, Na, General - Pain Management |
| Curonix LLC | $1,301.75 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $712.14 | 2023-2024 | Mild Device Kit |
| Medtronic, INC. | $612.85 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Osteocool Rf Ablation System |
| Abbott Laboratories | $388.64 | 2023-2025 | Proclaim |
| Relievant Medsystems, INC. | $381.25 | 2022-2023 | Intracept |
| Stryker Corporation | $248.10 | 2022-2025 | Mild Device Kit, Clottriever Bold Catheter |
| Spr Therapeutics, INC | $240.22 | 2023 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $231.59 | 2021-2025 | Belbuca |
| Nevro Corp. | $181.51 | 2022-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.59 | 2020-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $144.29 | 2020-2024 | Ztlido |
| Amgen INC. | $141.95 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $131.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $115.54 | 2022 | |
| Abbvie INC. | $108.71 | 2023-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $108.53 | 2025 | |
| Nalu Medical, INC. | $100.98 | 2022 | |
| Painteq LLC | $85.75 | 2023-2024 | Painteq |
| Forte Bio-Pharma LLC | $82.87 | 2023-2024 | Prolate, Nalocet |
| Ibsa Pharma INC. | $78.33 | 2023-2024 | Licart, Tirosint, Tirosint |
| Novo Nordisk INC | $43.64 | 2025 | Wegovy |
| Saluda Medical Americas, INC. | $37.84 | 2024-2025 | Evoke |
| Foundation Fusion Solutions, LLC | $22.65 | 2025 | |
| Averitas Pharma INC. | $22.50 | 2025 | Qutenza |
| Almatica Pharma LLC | $22.29 | 2022 | |
| Globus Medical, INC. | $19.77 | 2025 | Senza |
| Biohaven Pharmaceuticals, INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sankovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.